Bernhoven B.V.

At Bernhoven B.V., research in digestive system diseases focuses strongly on Crohn’s disease and ulcerative colitis. These studies are testing new treatment options and comparing them with placebo or existing care to better control inflammation, improve symptoms, and support long-term disease remission.

• Clinical trials in Crohn’s disease and ulcerative colitis
• Evaluation of new anti-inflammatory therapies
• Assessment of remission, symptom relief, and endoscopic response

Several studies also explore treatment strategies for patients who have not responded well to standard therapies, reflecting a strong interest in improving care for persistent and difficult-to-treat bowel disease.

The site’s Reumatologie department supports trials in musculoskeletal diseases, especially rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The research is aimed at finding better ways to manage inflammation and pain while also examining whether treatment can be safely reduced in patients whose disease is already well controlled.

• Studies in inflammatory arthritis and related conditions
• Testing treatment reduction and continuation strategies
• Focus on maintaining low disease activity and remission

This work is especially relevant for patients living with chronic joint and spine inflammation, where the goal is to balance effective control with long-term treatment burden.

Research in cardiovascular diseases and vascular disease at this hospital includes studies in high-risk heart disease, stroke prevention, and peripheral arterial disease. The trials are evaluating whether new or optimized treatment approaches can reduce major events such as heart attack, stroke, and other serious complications.

• Prevention of cardiovascular events in high-risk adults
• Research on stroke and antiplatelet treatment decisions
• Genotype-guided strategies for arterial thrombosis and limb outcomes

These studies aim to improve long-term protection for people with elevated cardiovascular risk and to support more personalized treatment choices.

Clinical trials in neoplasms cover several cancer types, including breast cancer, metastatic colorectal cancer, advanced cancer, chronic lymphocytic leukemia, and multiple myeloma. The research is centered on testing new therapies, refining treatment sequences, and exploring whether care can be adapted to improve effectiveness and tolerability.

• Breast cancer studies, including HER2-related disease
• Trials in colorectal cancer, leukemia, and multiple myeloma
• Evaluation of treatment effectiveness and treatment-sparing approaches

Across these oncology studies, the main goal is to improve outcomes while helping tailor therapy to the needs and risk profile of each patient.

Bernhoven B.V. is also involved in trials for respiratory tract diseases, bacterial infections, and otorhinolaryngologic diseases. These include studies on refractory chronic cough, acute respiratory tract infection, respiratory tract infection, invasive E. coli disease, and sudden hearing loss. The purpose is to test new therapies and improve recovery, symptom control, and prevention.

• Research on chronic cough and acute respiratory illness
• Studies of bacterial infection prevention
• Evaluation of new approaches for sudden hearing loss

This mix of trials shows a broad interest in both infection-related care and symptom-focused treatment for common but impactful conditions.

The site participates in research on nutritional and metabolic diseases and related organ complications, including non-alcoholic steatohepatitis and advanced chronic kidney disease. These studies are designed to assess whether new treatments can slow disease progression, protect organ function, and improve broader health outcomes.

• Trials in liver disease linked to metabolic dysfunction
• Kidney-focused research in severe chronic kidney disease
• Evaluation of clinical outcomes such as organ failure and hospitalization

By addressing both liver and kidney conditions, this research supports better management of long-term metabolic and organ-related disease burden.